ExodusPoint Capital Management’s Clearside Biomedical CLSD Stock Holding History

ExodusPoint Capital Management’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-852	Closed	-$19K	–	1930
2022 Q2	$19K	Buy	+852	New	+$20.7K	﹤0.01%	1854
2022 Q1	–	Sell	-1,959	Closed	-$81K	–	2242
2021 Q4	$81K	Buy	1,959 +393	+25%	+$25.5K	﹤0.01%	1982
2021 Q3	$141K	Buy	+1,566	New	+$138K	﹤0.01%	1850
2021 Q2	–	Sell	-1,326	Closed	-$49K	–	2404
2021 Q1	$49K	Buy	+1,326	New	+$66.6K	﹤0.01%	2030

Other funds holding CLSD

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $127M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ExodusPoint Capital Management's CLSD Position: Q3 2022 in Review

ExodusPoint Capital Management sold out of Clearside Biomedical (CLSD) in Q3 2022, closing a stake of 852 shares — an estimated $19K sold.

ExodusPoint Capital Management first reported a position in CLSD in Q1 2021 and held it in 4 quarters. The position peaked at $141K in Q3 2021. 54 funds tracked by Wall St. Rank hold CLSD as of Q3 2022.

ExodusPoint Capital Management reported no remaining Clearside Biomedical position as of Q3 2022 after selling out during the quarter.
ExodusPoint Capital Management sold 852 Clearside Biomedical shares in Q3 2022, an estimated $19K.
ExodusPoint Capital Management first reported a position in Clearside Biomedical in Q1 2021 and held it in 4 quarters.
ExodusPoint Capital Management's Clearside Biomedical position peaked at $141K in Q3 2021.
54 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2022.

Based on ExodusPoint Capital Management's 13F filing for Q3 2022, filed 10 Nov 2022.